ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1732 • ACR Convergence 2021

    Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2 and Ruru Guo3, 1Saint Agnes Healthcare, Baltimore, MD, 2Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (People's Republic), 3Renji Hospital, Shanghai, China (People's Republic)

    Background/Purpose: The efficacy of B cell activator factor/B lymphocyte stimulator inhibitors (BAFFi/BLySi) for systemic lupus erythematosus (SLE) has been proven in clinical trials. However, it…
  • Abstract Number: 1735 • ACR Convergence 2021

    Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

    Takehiro Nakai1, Futoshi Iwata1, Genki Kidoguchi1, Sho Fukui2, Hiroki Ozawa1, Satoshi Kawaai3, Yukihiko Ikeda1, Ayako Koido4, Masei Suda5, Atsushi Nomura6, Hiromichi Tamaki1, Kenichi YAMAGUCHI1 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, 3Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, 4St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, 5Suwa Central Hospital, Nagano, Japan, 6St. Luke's International Hospital, Nagareyama, Japan

    Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
  • Abstract Number: 1734 • ACR Convergence 2021

    Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

    Nadia Tchao1, Hamid Amouzadeh2, Nandita Sarkar1, Vincent Chow2, Xuguang Hu1, Mark Kroenke2, Hui Wang2, Rong Zhang2, Kevin Gorski1, Richard Furie3, Alan Kivitz4 and Stanley Cohen5, 1Amgen Inc., South San Francisco, CA, 2Amgen Inc., Thousand Oaks, CA, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 4Altoona Center for Clinical Research, Duncansville, PA, 5Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Diminished IL-2 as well as both quantitative and qualitative abnormalities in regulatory T cells (Treg) are associated with autoimmune diseases including SLE. Efavaleukin alfa…
  • Abstract Number: 1730 • ACR Convergence 2021

    Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS

    Anja Weiß1, Christina Bungartz1, Jutta Richter2, Susanna Späthling-Mestekemper3, Xenofon Baraliakos4, Peer Aries5, Rebecca Fischer-Betz6 and Anja Strangfeld7, 1DRFZ, Berlin, Germany, 2Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, 3Rheumapraxis München, München, Germany, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 5Rheumatologie in Hamburg, Hamburg, Germany, 6Uniklinik Dsseldorf, Dsseldorf, Germany, 7Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: SpA is a severe chronic inflammatory disease, which affects quality of life and functional status. It frequently occurs in women of childbearing age. Active…
  • Abstract Number: 1714 • ACR Convergence 2021

    Exploring the Sexual and Reproductive Health (SRH) Needs of Men with Rheumatic Diseases

    Olivia Stransky1, Nicole Hunt2, John Richards3 and Mehret Birru Talabi1, 1University of Pittsburgh, Pittsburgh, PA, 2UPMC, Pittsburgh, PA, 3Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA

    Background/Purpose: Few studies have comprehensively evaluated the information needs and priorities that men with rheumatic diseases have about their sexual and reproductive health (SRH). This…
  • Abstract Number: 1741 • ACR Convergence 2021

    Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials

    Kenneth Kalunian1, Maria Dall'Era2, Richard Furie3, Eric Morand4, Konstantina Psachoulia5, Emmanuelle Maho6, Catharina Lindholm7 and Raj Tummala5, 1University of California, La Jolla, CA, 2University of California San Francisco, San Francisco, CA, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: In 2 phase 3 trials, TULIP-1 and TULIP-2, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 Here, we…
  • Abstract Number: 1740 • ACR Convergence 2021

    Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials

    Richard Furie1, Eric Morand2, Kenneth Kalunian3, Konstantina Psachoulia4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala4, 1Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 2Monash University, Melbourne, Australia, 3University of California, La Jolla, CA, 4BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity in patients with SLE.1,2 We investigated…
  • Abstract Number: 1733 • ACR Convergence 2021

    Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

    Martin Aringer1, Ian N. Bruce2, Richard Furie3, Eric Morand4, Emmanuelle Maho5, Catharina Lindholm6 and Raj Tummala7, 1University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, 2University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 3Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 4Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
  • Abstract Number: 1739 • ACR Convergence 2021

    SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials

    Susan Manzi1, Richard Furie2, Eric Morand3, Yoshiya Tanaka4, Gabriel Abreu5, Catharina Lindholm5 and Raj Tummala6, 1Allegheny Health Network, Pittsurgh, PA, 2Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, 3Monash University, Melbourne, Australia, 4University of Occupational and Environmental Health, Kitakyushu, Japan, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab, a type I IFN receptor mAb, improved disease activity versus placebo in patients with moderate…
  • Abstract Number: 1705 • ACR Convergence 2021

    The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users

    Marco Gianpiero Antivalle1, Michele Agosti1, Giuliana La Paglia2, Alberto Batticciotto3, Maria Chiara Ditto4, SIMONE PARISI5 and Piercarlo Sarzi-Puttini6, 1L. Sacco University Hospital, Milano, Italy, 2L.Sacco University Hospital, Milano, Lombardia, Italy, 3Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, 4AOU Città della Salute e della Scienza, Torino, Italy, 5AOU Città della Salute e della Scienza, TURIN, Italy, 6L.Sacco University Hospital, Milano, Italy

    Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
  • Abstract Number: 1727 • ACR Convergence 2021

    Behcet’s Disease: A Meta-analysis of Pregnancy Outcomes

    Leah Rooney1, Aine Gorman2, Matthew Turk3, Louise Moore4, Celine O'Brien5, Jared Bierbrier6, Anne Clohessy5, Eamonn Molloy7, Lorraine O Neill8, Fionnuala M. Mc Auliffe5 and Douglas Veale9, 1St Vincent's University Hospital, Dublin, Ireland, 2St Vincents Hospital, Dublin, Ireland, 3St. Vincents University Hospital, Dublin, Ireland, 4Our Lady's Hospice and Care Services, Harold's Cross, Dublin 6W, Kinnegad, Ireland, 5Perinatal Research Centre, Obstetrics and Gynaecology, School of Medicine, University College Dublin and National Maternity Hospital, Dublin, Dublin, Ireland, 6McMaster University, Hamilton, ON, Canada, 7St Vincent's Healthcare Group, Dublin, Ireland, 8St. Vincent's Hospital, Dublin, Ireland, 9University College Dublin, Dublin, Ireland

    Background/Purpose: Behcet’s disease is a systemic inflammatory disease which commonly presents with episodes of acute inflammation, oral and genital ulcers, uveitis and skin lesions. It…
  • Abstract Number: 1718 • ACR Convergence 2021

    Use of Gonadotropin Releasing Hormone Agonist for Ovarian Preservation in SLE Patients on Cyclophosphamide

    Jun Chu1, Alice Fike2, Michael Davis3, Zerai Manna4, Komal Ejaz5, Yenealem Temesgen-Oyelakin6, Elaine Poncio7, Isabel Ochoa7, Alan Decherney4 and Sarfaraz Hasni4, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3NIAMS, Bethesda, MD, 4National Institutes of Health, Bethesda, MD, 5Sheikh Zayed Medical College, Scranton, PA, 6National Institutes of Health (NIH), Bethesda, MD, 7NIH/NIAMS, Bethesda, MD

    Background/Purpose: SLE is an autoimmune disease which predominantly affects women of childbearing age (age 20-40). Most of the medications used for treating SLE can adversely…
  • Abstract Number: 1722 • ACR Convergence 2021

    Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark

    Anne Emilie Secher1, Karin Hellgren2, Bente Glintborg3, Ane Rom4, Merete Hetland5 and Fredrik Granath2, 1COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, 2Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 3COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, 4The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, 5DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark

    Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
  • Abstract Number: 1597 • ACR Convergence 2021

    Arthritis Patient Perspectives on Virtual Care for People Living with Arthritis During the COVID-19 Pandemic and for the Future

    Maya Joshi1, Anita Chan1, Adriana Lima2, Kelly Lendvoy1, Eric Sayre2 and Cheryl Koehn1, 1Arthritis Consumer Experts, Vancouver, BC, Canada, 2Arthritis Research Canada, Richmond, BC, Canada

    Background/Purpose: Virtual Care (VC) is the delivery of health care services and information by electronic methods (video, smartphones, email, text) and may support arthritis patients…
  • Abstract Number: 1610 • ACR Convergence 2021

    “You Can’t Touch, You Can’t Bond”: COVID-19 and Telehealth Impacts on Communication, Goals, and Experience of Care for Persons with Rheumatoid Arthritis and Their Clinicians

    Elizabeth Hulen1, Christopher Larsen2, Rachel Matsumoto2, Patricia Katz3 and Jennifer Barton4, 1VA Portland Health Care System, Portland, OR, 2Center to Improve Veteran Involvement in Care/VA Portland Health Care System, Portland, OR, 3University of California San Francisco, San Francisco, CA, 4VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: A rapid shift to telehealth visits has been a key part of health system response to the ongoing COVID-19 pandemic. This study explores the…
  • « Previous Page
  • 1
  • …
  • 546
  • 547
  • 548
  • 549
  • 550
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology